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 A cross-sectional analysis that included 1378 HIV-uninfected 
female participants aged 15-49 was conducted to investigate the 
association between hormonal contraceptive use and high-risk human 
papilloma virus (HR-HPV) prevalence in Rakai, Uganda. Hormonal 
contraception (HC) use consisted of injectable DMPA (n=126), oral 
contraception (n=25) and implants (n=3) in this study. 
The analysis was stratified by age into two groups 15 to 29 and 30 
to 49 years, because HR-HPV in the older women was most relevant to 
the risk of cervical neoplasia. The overall prevalence rate of infection 
with HR-HPV decreased with older age for both the HC users (exposure 
group) and non-pregnant and non-HC users (reference group). 
The results showed that the use of hormonal contraceptive was not 
associated with increased prevalence rate of HR-HPV after controlling 
for other covariates including age, number of sexual partners in the 
previous year, condom use in previous year, educational level and current 
pregnancy or breastfeeding status. (Crude prevalence risk ratio 
(PRR)=1.064, P-value=0.57). After adjusting for other covariates in the 
log-binomial model, the association between HC use and the risk of 
infection with HR-HPV was not statistically significant for the two age 
groups. Female participants aged 15 to 29 had an adjusted PRR=1.043, P-
 iii 
value=0.73 and participants aged 30 to 49 had an adjusted PRR=1.059 
with P-value=0.83. 
Conclusion: Hormonal contraceptive use by female participants 
was not significantly associated with increased prevalence of infection 
with HR-HPV and the effect of interaction between HC use and age on 
the risk of infection with HR-HPV is not statistically significant.  
More research is needed to examine the effect of HC use on HPV 
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Infection with human papillomavirus (HPV) is prevalent among 
individuals who are sexually active in developing countries.1 Moreover, 
developing countries contribute to more than 85% of the HPV disease 
burden in the world. 2 HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68 are considered to be the primary high-risk 
(oncogenic) types of HPV (HR-HPV denotes high risk HPV) and 
genotypes 6, 11, 26, 40, 42, 43, 53, 54, 55, 61, 67, 70, 71 72, 73, 81 82, 
83, 84, and 108 are considered to be low-risk (non-oncogenic) types of 
HPV. High-risk genotypes of HPV cause cervical, vulval and anal cancer 
among women and penile and anal cancers among men.3  
There are over 490,000 cases and 250,000 deaths from cervical 
cancer each year worldwide, which makes cervical cancer the second 
most common female cancer in the world. 4 Cervical cancer in eastern 
Africa has the highest incidence and mortality rate from cancer. In 2008, 
the estimated age standardized rates (ASR) mortality and incidence rates 
of cervical cancer are 25.3 deaths/1000 people and 34.5 new cases/1000 
person years, respectively in eastern Africa.2 A meta-analysis conducted 
in 2007 summarized the prevalence of HR-HPV of different regions in 
the world, in which Eastern Africa had both the highest crude and 
adjusted HPV prevalence.1 Approximately 20 million women in sub-
 2 
Saharan Africa use hormonal contraceptives with 55% of them using 
injectable DMPA and hormonal contraceptive use is becoming more 
prevalent in eastern Africa. 5 Long duration of hormonal contraceptive 
(HC) use is associated with increased risk of diagnosis of cervical cancer 
in several case-control studies6 and infection of HR-HPV is a necessary 
but not sufficient cause of most cervical cancers. 7  Therefore, the 
association between hormonal contraceptive use and infection with HR-
HPV is of considerable importance because infection with HR-HPV in 
hormonal contraceptive users could increase cervical cancer risk. 
However, the conclusions of studies investigating the associations 
between hormonal contraceptive use and risk of infection with HR-HPV 
are not consistent. Some studies reported weak associations and some 
reported strong associations. The adjustments for other risk factors such 
as age, condom use and number of sexual partners were also limited for 
some studies. 8 Moreover, the findings of some studies investigating the 
association between oral contraceptive use and risk of infection with HR-
HPV8 9may not be generalized to eastern Africa area where the major 
type of hormonal contraceptive used in eastern Africa is injectable 
DMPA.  
Therefore, this cross-sectional study was conducted to assess the 
association between the female HC use (including injectable DMPA, 
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implants and oral contraception) and the risk of infection with HR-HPV 
in female participants in Rakai, Uganda. Results of this cross-sectional 
analysis could provide preliminary information of the association 
between HR-HPV positivity among women in eastern Africa and 













2.1.Data collection process and selection criteria:  
        Two clinical trials enrolled male participants and their female 
partners were conducted in Rakai, Uganda from 2003 to 2006 to assess 
the effectiveness of male circumcision for the prevention of HIV 
infection in men and transmission of HIV to their female partners. 
Another objective of these two studies was to assess the effectiveness of 
male circumcision for prevention of other sexually transmitted infections 
including HR-HPV in men and transmission of HR-HPV to their female 
partners.10 11 
The goal of this cross-sectional analysis was to investigate the 
association between female hormonal contraception use and the risk of 
prevalent infection with HR-HPV in female participants, utilizing the 
baseline data collected from the two clinical trials of male circumcision 
mentioned above. 
During the enrollment process of these trials, female partners of the 
male participants who were married or in long-term consensual unions 
were invited to participate the study after providing written informed 
consent. The consent forms informed women of the potential risks, 
benefits and the procedures of the clinical trials and that participation 
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totally voluntary. 11 
          During the enrollment visit, female participants were interviewed 
by fieldworkers to record information about their socio-demographic 
characteristics, pregnancy or breastfeeding status, history of condom use 
by herself or male partners in the last 12 months, history of alcohol use 
before last sex, number of sexual partners in the last 12 months, current 
use of family-planning methods including HC use and symptoms of 
genital-tract infections (genital ulcer disease, vaginal discharge, and 
dysuria). Female participants were also asked to provide self-collected 
vaginal swabs for HPV detection and the HPV genotyping was done with 
the Roche HPV Linear Array (Roche Diagnostics, Indianapolis, IN, 
USA).11  
2.2.HPV detection and HIV testing  
Vaginal swabs were stored in specimen transport medium at -800 C 
(Digene Corporation, Gaithersburg, MD, USA). Only vaginal swabs with 
β-globin gene or viral DNA or both were included in this analysis. HPV 
genotyping used the Roche HPV Linear Array (Roche Diagnostics, 
Indianapolis, IN, USA). The high-risk genotypes of HPV were genotypes 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. HIV status was 
determined by two separate ELISAs tests, and discordant ELISA results 
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were confirmed by HIV-1 western blot. 11 
2.3.Study design: 
This cross-sectional analysis utilized the baseline data of HIV-
uninfected female participants collected by the two clinical trials. The 
infection with HR-HPV was defined as at least one type of HR-HPV. 
Female participants who were HIV positive at baseline were 
excluded from the data analysis since HIV infection is strongly associated 
with higher rates of infection and persistence of HR-HPV.12 
Family planning methods in this study included oral contraceptives, 
injectable DMPA, implants, male condoms, spermicides, and intrauterine 
devices (IUD). The exposure to HC was defined as self-reported current 
use of one of the three contraceptive methods: Oral contraceptive, 
injectable DMPA and implant.5 All women currently using HCs, used 
one of the three HC methods listed above. Among female participants 
who were currently pregnant or breastfeeding, none reported current use 
of HCs, and pregnancy status of female participants was treated as a 





The enrollment socio-demographic characteristics, sexual 
behaviors and symptoms of STI for female participants were tabulated to 
assess the overall relevant information of female participants users. 
The differences in characteristics between HC users and non-HC 
users were assessed by two-sided χ2 test or Fisher’s exact test. If the 
distribution of characteristics was statistically different with a P-
value<0.05, multivariate analysis adjusting for that factor was used to 
account for potential confounding.  
It is well established that HR-HPV age-specific prevalence is U 
shaped, higher in the young, decreasing with age and gradually increasing 
when women become older.13 In addition, we wanted to assess whether 
there is an interaction between HC use and age on the risk of infection 
with HR-HPV. Therefore, female participants were stratified into 15 to 
29 and 30 to 49 age groups age groups. 
The prevalence rate ratios of infection with HR-HPV associated 
with HC users relative to non-pregnant, non-HC users (reference group), 
stratified by age, were tabulated to assess the interaction between HC use 
and age on risk of infection with HR-HPV. Pregnant female participants 
were excluded from the reference group. The 95% CIs and p-values of 
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prevalence risk ratios were obtained by unconditional maximum 
likelihood and Wald test respectively. 
Unadjusted and adjusted prevalence risk ratios of infection with 
HR-HPV and their corresponding 95% confidence intervals associated 
with HC users relative to non-HC users were estimated by fitting log-
binomial model. 14  Log-binomial models are usually employed when 
estimating prevalence risk ratios in cohort studies or clinical trials. 
Covariates included in the multivariate log-binomial model were age, 
educational levels, number of sexual partners in the last 12 months, 
condom use by either the female participant or male partners in the last 
12 months and current self-report of HC use. Educational level and 
number of sexual partners in previous year were included in the 
multivariate analysis since they were risk factors for infection with HR-
HPV in other studies.1516 The use of condoms in the last 12 months was 
also adjusted in the model because condom use could potentially lower 
the risk of HR-HPV.  
A sensitivity analysis was conducted to estimate the relative risk of 
infection with HR-HPV associated with HC users relative to non-
pregnant and non HC-users by further excluding female participants who 
used condoms in the last 12 months and having more than one sexual 
partners in the previous year to test if the results were robust. 
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The statistical analysis was performed using R and STATA version 
13. R package “epitools” and “glm” function associated with multivariate 














There were 1378 HIV-uninfected women in this analysis. At 
enrollment, the proportion of vaginal swabs with amplifiable cellular 
DNA was 99.56% (1372/1378). The prevalence rate of infection with 
HR-HPV was 36.52% (501/1372). 
  The socio-demographic characteristics of female participants are 
summarized in Table 1. There were 1029 (74.64%) female participants 
aged 15 to 29 and 349 (25.33%) female participants aged 30 to 49. The 
majority of female participants 1320 (95.8%) had one sexual partner in 
the prior year and 57 (4.2%) female participants reported more than one 
sexual partner in the previous year. Non-use of condoms in the previous 
year was reported by 1135 (82.44%) female participants or their male 
partners, and 242 (17.56%) female participants or their male partners 
used condoms in the previous year. The percent of female participants 
reported current use of HC method was 154 (11.2%) and 1224 (88.8%) 
did not use HCs. The number of female participants who were currently 

















30-49   349(25.33%) 
  
Marital Status  
 
Polygamous union       24(1.75%) 
Monogamous  1353(98.25%) 
  
Number of sex partner in previous year 
1 1320(95.8%) 
>1        57(4.2%) 
  
Alcohol drinking before sex  
 Never   917(66.54%) 
Sometimes/Inconsistent   461(33.46%) 
  
Condom use in previous year  
 
Used condom in previous year    242(17.56%) 
Not used condom in previous year 1135(82.44%) 
  
Religion 
 None          5(0.36%) 
Catholic    839 (60.89%) 
Muslim          48(3.48%) 
Protestant      380(27.58%) 
Pentecostal        106(7.69%) 
  Educational levels  
 
None/Primary   1198(87.25%) 
Secondary/Post Secondary      175(12.75%) 
  
Current report of HC use  
 
Using any of the HC method         154(11.2%) 
Not using HC method      1224 (88.8%) 
  
Different types of HC method  
 
Pills & Norplant          28(2.03%) 
Injection         126(9.1%) 
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              The socio-demographic characteristics of HC users and Non HC-
users and comparisons of the differences between the two groups are 
summarized in Table 2. Most of the socio-demographic characteristics 
were comparable except educational levels in which HC users tend to 
have higher educational level compared with non-HC users (P-
value=0.00013). Therefore, educational level was adjusted in the 
multivariate analysis in case it is associated with different risk of 





Pregnant or breastfeeding 
 
Currently pregnant or breastfeeding      305(22.13%) 
Currently Not pregnant or breastfeeding   1073(77.87%) 
  
Self reported STI symptoms previous year 
Genital ulcer disease     193(14.01%) 
Urethral or Vaginal discharge     648(47.02%) 
Dysuria     275(19.96%) 
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Non HC user     (N=1224) 
 
χ2 test or Fisher’s 
exact test 
P-values 















     
Marital Status 









     Number of Sex partners in 
previous year 










     
Alcohol use before sex 









     
Religion 








  Protestant/CoU 42(27.27%) 
 
338(27.73%) 




     
Educational level 









     
Condom use in previous year 








    *Condom use in previous year refers to either female participants use or male partners use 







Table 3 summarizes the crude prevalence risk ratios with their P-
values. The crude prevalence risk ratios for female participants aged 30 to 
49 is less than 1 with P-value=0.002 which is consistent with the general 
finding that older women have lower prevalence of HR-HPV infection. 
The number of sexual partners in previous year was a risk factor for 
infection with HR-HPV with P-value<0.0001. The use of condom was 
shown to be a risk factor with crude PRR 1.218 (P-value=0.02) because 
women who used condoms in the last 12 months tend to have more 
sexual partners in the last 12 months (14.3%=34/238) compared with 
women who didn’t use condom in the last 12 months (2%=23/1133). The 
pregnancy or breastfeeding status was not associated with the prevalence 
of infection with HR-HPV, which is consistent with results of several 
cohort studies.17 18 We did not observe a significant association between 








Table 3. Crude Prevalence Risk Ratios for each covariate by fitting Univariate Model 
Covariates 
 
Number of HPV/N 
 






        15-29 
 
400/1026(38.99%) 









         Education levels 
        None/ primary 
 
431/1192(36.16%) 









         Number of sex partner in 
preprevious year 












      
         Condom use in previous 
year  












      
         HC use 












               D  Pregnancy Status 
 
        Yes  
 
382/1069(35.73%) 









 The 95% CI of each covariate was obtained by taking exponentiate of the 95% Wald’s 
confidence interval. 
 
In Table 4, the prevalence risk ratios of infection with HR-HPV 
associated with HC users relative to non-pregnant and non-HC users 
(reference group in Table 4) stratified by four age groups were tabulated 
to further explore the relationship between age and HC use. This showed 
the prevalence of HR-HPV for both the exposure group and the reference 
group decreased with age until age 35 and increased in the age interval 36 
to 49 years, which is consistent with the literature. 13 The estimated 
prevalence risk ratios of infection with HR-HPV were all above one and 
peaked during the middle age groups. Figure 1 illustrates the same results 
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of Table 4 using scatterplot to visualize the trend. 
   Table 4. Prevalence Risk Ratios of Infection with HR-HPV Associated with HC users 
relative to non-pregnant and non-HC users 
Age 
Group  
       Number of HR-HPV/ (%) 
 
      95% CI of PRR 
 
     P-Values  
[15,24) 
 






Reference group 176/428(41.12%) 
    
       [25,29] 
 






Reference group   80/245(32.65%) 
    
       [30,35] 
 






Reference group    32/137(23.36%) 
    
       [36,49] 
 






Reference group 35/106(33.02%) 
     The 95% CI of each age group was obtained by taking exponentiate of the 95% Wald’s 
confidence interval. 
 The reference group in Table 4 refers to female participants who were non-HC users and not 


















Age Groups                       [15,24]             [25,29]             [30,35]         [36,49]
Figure 1.Comparison between percent of HR-HPV infection 








Table 5 summarizes the prevalence risk ratios of infection with 
HR-HPV associated with HC-users relative to non-pregnant and non-HC 
users stratified by two age groups. Female participants aged 15 to 24 and 
25 to 29 were combined together since the prevalence of HR-HPV for 
HC users were similar in these two groups and female participants aged 
30 to 35 and 36 to 49 were combined together since there were relatively 
few people in these two age groups. The estimates of risk ratios for two 
age groups were both higher than 1. 
Table 5. Prevalence Risk Ratios of infection with HR-HPV associated with HC users 
relative to non-pregnant and non-HC users 
Age 
Group  
Number of HR-HPV/ (%) 
 






HC use 45/110(40.91%) 
 
1.08(0.84   1.37)            0.56 
 
  
Reference group 256/673(38.04%) 
   
       [30,49] 
 
HC use 14/43(32.55%) 
 
  1 .18(0 .73   1.9)            0.49 
 
  
Reference group 67/243(27.55%) 
 
                                      
  The 95% CI of each age group was obtained by taking exponentiate of the 95% Wald’s 
confidence interval. 
 The reference group in Table 5 refers to female participants who were non-HC users and              
not pregnant or breastfeeding.  
   
 Table 6 summarizes the adjusted prevalence risk ratios and 
associated 95% confidence intervals as well as p-values for each of the 
covariates in the multivariate log-binomial model. After adjusting for 
other covariates including age, educational level, use of condom in the 
previous year, number of sexual partners in the previous year and current 
status of pregnancy or breastfeeding, association between HC use and the 
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risk of infection with HR-HPV was not statistically significant. In 
addition, the interaction between age and HC use on the effect of 
infection with HR-HPV was also shown to be statistically insignificant. 
Female participants who aged 30 to 49 have prevalence risk ratio 0.758 
with P-value=0.005 indicating that the risk of infection with HR-HPV for 
older female participants is less than younger women.  The number of 
sexual partners in the previous has relative risk 1.565 with P-
value<0.0001 showing that being sexually active is an important risk 
factor of getting infection with HR-HPV 
Table 6. Adjusted Prevalence Risk Ratios of infection with HR-HPV for Covariates in 
Multivariate Log-binomial model  
Covariates and Interaction term  
 
 Adjusted    
PRR 
 
95% CI of Adjusted PRR 
 
Adjusted PRR   
P-values 




[0.62   0.92] 
 
0.01 




[0.84   0.25] 
 
0.78 




[1.22   2.01] 
 
<0.0001 











[0.92   1.27] 
 
0.35 




[0.82   1.33] 
 
0.73 








) = b0 + b1 ´HC + b2 ´age+ b3 ´condom + b4 ´ sexp+ b5 ´edu + b5 ´ preg+ b6 ´age´HC
. 
 Covariates HC=1 represents self-report of current hormonal contraceptive method.                              
Age has two categories and reference level is women aged 15 to 29. Condom=1 represents the 
using of condom use in the last 12 months. Sexp=1 represents whether the number of sexual 
partners in the last 12 months is more than one. Edu=1 represents female participants received 
secondary or post secondary education. Preg=1 represents female participants are currently 
pregnant. Age*HC represents the interaction term between Hormonal Contraceptive Method 
and Age. 
 






   Table 7 summarized the results of sensitivity analysis after 
excluding female participants who used condom and having more than 
one sexual partners in the previous year from both the HC use group and 
reference group. We can see the results of Table 6 did not differ much 
from Table 4 implying that the result is robust. 
 
Table 7.Sensitivity Analysis: Prevalence risk ratios of infection with HR-HPV 
associated with HC users relative to reference group* 
     Age Group 
 
Number of HR-HPV/N   (%) 
 





HC use*     40/89(44.94%) 
 




Reference group* 187/536(34.89%) 
    
             [30,49] 
 
HC use *    11/35(31.43%) 
 




Reference group*  49/202(24.26%) 
        The 95% CI of each age group was obtained by taking exponentiate of the 95% Wald’s   
confidence interval. 
 The HC user* refer to female participants who were currently using HC method and didn’t 
use condom in the previous year and had only one sex partner in previous year. 
 The reference group* in table 7 refers to female participants who were non-HC users and 
non-pregnant or breastfeeding, didn’t use condom in the previous year and had only one sex 













 The results suggest that there was no statistically significant 
association between hormonal contraceptive use and the prevalence of 
infection with HR-HPV for female participants. The number of sexual 
partners in the last 12 months is an important risk factor of infection with 
HR-HPV and female participants aged 30 to 49 have lower risk of 
infection with HR-HPV compared with women aged 15 to 29.   
Hormonal contraceptive use was shown not to be a risk factor for 
infection with HR-HPV among female participants in Rakai, Uganda. 
There are three hypotheses about the mechanisms of how hormonal 
contraceptives make women more likely to develop cervical cancers: 1) 
HC use could increase the risk of cervical cancer by increasing the 
acquisition of HR-HPV 2) HC use could modify the host immune 
responses to HR-HPV so that HR-HPV becomes more persistent 3) HC 
use could increase the risk of development of pre-cancerous lesions.6 As 
mentioned before, this cross-sectional analysis could not investigate any 
of the three hypotheses, but could provide information on the necessity of 
conducting studies to explore whether HC use might increase the 
acquisition or persistence of HR-HPV or both. 
There are limitations to this research. Firstly, this was a cross 
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sectional analysis focusing on the HR-HPV prevalence of female 
participants at baseline which was primarily a descriptive analysis. The 
casual effect between hormonal contraceptive use and the prevalence of 
HR-HPV could not be assessed. Secondly, all the female participants in 
this study were either married or in a long-term consensual relationship. 
Therefore, we couldn’t generalize the results of this research to unmarried 
or non-consensual relationships. Thirdly, we only recorded current reports 
of HC-use therefore the effect of duration of HC use on the prevalence of 
HR-HPV were not assessed. Fourthly, the sample size of hormonal 
contraceptive users aged 30 to 49 is small in this study yielding limited 
power to detect an effect between hormonal contraceptive and prevalence 
of infection with HR-HPV. 
In conclusion, we did not observe an association between HC use 
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